TFBS Bioscience Inc.

NT$19.40As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6939Healthcare

Country Taiwan

PE (Fwd) —

TSR 3Y CAGR (29.66%)

Div yield —

ROE (6.22%)

Diagnostics & Research

Beta (5Y) —

PE TTM —

TSR TTM (23.17%)

Mkt cap NT$686.5M

ROIC (7.82%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$20

4.11%

(34.13%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

193.1

RevenueNT$M

—

252.7

231.9

180.6

193.1

187.1

(8.57%)

—

6.97

Revenue growth%

—

(8.23)

(22.15)

6.97

(3.14)

(8.23)

—

19.06

Gross margin%

—

41.17

33.56

20.78

19.06

18.59

27.17

—

(40.39)

Operating margin%

—

13.36

(1.92)

(33.91)

(40.39)

(41.34)

(17.92)

—

(38.58)

Net margin%

—

10.96

2.12

(21.42)

(38.58)

(39.13)

(9.65)

—

P/E ratio (avg)x

—

384.1

—

384.1

—

EV/EBITx

—

(34.69)

FCF yield (avg)%

—

(1.03)

(24.36)

(26.91)

(27.60)

(24.36)

—

(121.75)

FCF margin%

—

11.43

(8.35)

(190.50)

(121.75)

(100.00)

(65.05)

—

3.156

FCF / Net incomex

—

1.043

(3.943)

8.894

3.156

—

2.099

—

(7.82)

ROIC%

—

10.79

(1.15)

(8.90)

(7.82)

(6.79)

(4.48)

—

(6.22)

Return on equity%

—

2.24

0.39

(3.10)

(6.22)

(6.49)

(1.35)

—

(5.11)

Return on assets%

—

2.03

0.34

(2.58)

(5.11)

(5.28)

(1.12)

—

(2.13)

EPSNT$

—

0.80

0.14

(1.11)

(2.13)

(2.10)

(82.55%)

—

(92.15)

EPS growth%

—

(82.55)

(899.14)

(92.15)

1.75

(92.15)

—

33.32

Bookvalue per shNT$

—

35.56

35.67

35.38

33.32

31.22

(2.14%)

—

(6.73)

FCF per shareNT$

—

0.83

(0.55)

(9.87)

(6.73)

(5.35)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

35.38

Shares (diluted)M

—

34.80

35.34

34.84

34.94

◌34.94

0.14%

—

(0.28)

Buyback yield%

—

(1.57)

1.42

(0.28)

◌—

(0.28)

—

0.193

D/E ratiox

—

0.042

0.105

0.159

0.193

0.206

0.132

—

0.604

Enterprise valueNT$B

—

1.088

1.092

0.792

0.783

(14.70%)

—

LT debtNT$M

—

Peers (US$18.57M)

Cap (US$)

Kim Forest Enterprise…

23.25M

—

Sofiva Genomics Co.…

21.39M

102.4x

Pharmigene, Inc.

12.27M

—

King International…

18.88M

80.28x

Capital

TTM

10Y

Leveragex

—

(13.87)

EBIT/Intx

(27.74)

(17.57)

Own earn%

—

Sh yield%

(0.28)

Owners

Insiders/Inst%

15.42

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

2/4

Revenue growth years

1/3

EPS growth years

0/3

Dividend streakyrs

Op margin range%

−40–13

$1 testx

—

Incr. ROIC%

—

TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$193.1M

(8.57%)

1.00×

Cost of revenue

NT$156.3M

1.69%

1.38×

Operating expenses

NT$114.8M

17.78%

2.14×

Asset mix

Trend

Other

78.93%

Cash and investments

21.07%

Reinvestment returns

No breakdown available